Cadila Healthcare trades higher on the BSE
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cadila Healthcare is currently trading at Rs. 626.25, up by 3.80 points or 0.61% from its previous closing of Rs. 622.45 on the BSE.
The scrip opened at Rs. 625.00 and has touched a high and low of Rs. 633.20 and Rs. 619.95 respectively. So far 270987 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 333.10 on 27-May-2020.
Last one week high and low of the scrip stood at Rs. 640.00 and Rs. 608.00 respectively. The current market cap of the company is Rs. 64260.32 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.53% and 8.40% respectively.
Zydus and TLC, a specialty pharmaceutical company in Taiwan, have signed a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
